Item 6. Exhibits

The following documents are filed as a part of this Quarterly Report:


Exhibit						Description
3.1						Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022

3.2						Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022

10.1						The Lilly Directors' Deferral Plan, as amended (1)*

31.1						Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*

31.2						Rule 13a-14(a) Certification of Lucas Montarce, Executive Vice President and Chief Financial Officer*

32						Section 1350 Certification*

101						Interactive Data Files (embedded within the Inline XBRL document)*

104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

(1) Indicates management contract or compensatory plan. * Filed herewith.

Long-term debt instruments under which the total amount of securities authorized does not exceed 10 percent of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the Securities and Exchange Commission upon request.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


		ELI LILLY AND COMPANY
		(Registrant)

Date:	August 5, 2026	/s/ Lucas Montarce
		Lucas Montarce
		Executive Vice President and Chief Financial Officer
Date:	August 5, 2026	/s/ Donald Zakrowski
		Donald Zakrowski
		Senior Vice President, Finance, and Chief Accounting Officer

Previous: Item 5. Other Information